ARAna Margarida Sobrinho Ribeiro

Ana Margarida Sobrinho Ribeiro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ana Margarida Sobrinho Ribeiro has a total of 8 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • First Psychotic Episode: Panhypopituitarism and Psychosis in a Female Patient

    by Marta Sofia De Macedo e Castro, Ana Margarida Sobrinho Ribeiro

    Endocrine and psychiatric disorders frequently overlap, and neuropsychiatric symptoms can be the primary manifestation of an underlying endocrinopathy. This case report describes a 69-year-old Caucasian female admitted to a psychiatry department with severe persecutory and mystical delusions, auditory-verbal and visual hallucinations, and alopecia. Further investigation revealed a psychotic disorder attributed to panhypopituitarism, secondary to poor adherence to hormone replacement therapy following a pituitary resection in 1990. Following treatment optimization, the patient showed remarkable clinical improvement and was discharged after 31 days. This case highlights that while psychosis is a rare presentation of panhypopituitarism, it is crucial to rule out treatable organic etiologies in patients presenting with acute psychiatric features, preventing diagnostic delays and ensuring appropriate targeted therapy.

  • Outcome and risk factors assessment for adverse events in advanced esophageal cancer patients after self-expanding metal stents placement

    by E. Rodrigues-Pinto, P. Pereira, R. Coelho, P. Andrade, A. Ribeiro, S. Lopes, P. Moutinho-Ribeiro, G. Macedo

    Self-expanding metal stents (SEMS) are the treatment of choice for advanced esophageal cancers. Literature is scarce on risk factors predictors for adverse events after SEMS placement. Assess risk factors for adverse events after SEMS placement in advanced esophageal cancer and evaluate survival after SEMS placement. Cross-sectional study of patients with advanced esophageal cancer referred for SEMS placement, during a period of 3 years. Ninety-seven patients with advanced esophageal cancer placed SEMS. Adverse events were more common when tumors were located at the level of the distal esophagus/cardia (47% vs 23%, P = 0.011, OR 3.1), with statistical significance being kept in the multivariate analysis (OR 3.1, P = 0.018). Time until adverse events was lower in the tumors located at the level of the distal esophagus/cardia (P = 0.036). Survival was higher in patients who placed SEMS with curative intent (327 days [126–528] vs. 119 days [91–147], P = 0.002) and in patients submitted subsequently to surgery compared with those who did just chemo/radiotherapy or who did not do further treatment (563 days [378–748] vs. 154 days [133–175] vs. 46 days [20–72], P < 0.001). Subsequent treatment kept statistical significance in the multivariate analysis (HR 3.4, P < 0.001). SEMS allow palliation of dysphagia in advanced esophageal cancer and are associated with an increased out-of-hospital survival, as long as there are conditions for further treatments. Tumors located at the level of the distal esophagus/cardia are associated with a greater number of adverse events, which also occur earlier.